The Linear No-Threshold Relationship Is Inconsistent with Radiation Biologic and Experimental Data

The carcinogenic risk induced by low doses of ionizing radiation is controversial. It cannot be assessed with epidemiologic methods alone because at low doses the data are imprecise and often conflicting. Since the 1970s, the radiation protection community has estimated the risk of low doses by means of extrapolation from the risk assessed at high doses, generally by using the linear no-threshold (LNT) model.

The LNT relationship implies proportionality between dose and cancer risk. This approach is based on one set of data and two hypotheses: (a) The relationship between dose and DNA damage in vivo seems linear from 1 mGy to 100 Gy with use of H2AX foci as a marker for DNA double-strand breaks (DSBs)—however, this marker is not specific (1); (b) each DSB is hypothesized to have the same probability of inducing cell transformation, irrespective of the quantity of DSBs present simultaneously in the cell; and (c) each transformed cell is hypothesized to have the same probability of developing into an invasive cancer, irrespective of the dose delivered to the tissue. The advances during the past 2 decades in radiation biology, the understanding of carcinogenesis, and the discovery of defenses against carcinogenesis challenge the LNT model, which appears obsolete (2–6).

Life developed in a bath of ionizing radiation and solar ultraviolet radiation and created aerobic organisms requiring (a) defenses against the metabolically induced reactive oxygen species, (b) DNA repair, and (c) elimination of damaged cells. Several sets of data show the efficacy of these defenses to be much higher at low than at high doses and for fractionated or protracted irradiation than for acute irradiation.

The LNT model was introduced as a concept to facilitate radiation protection (7). But the use of this model led to the claim that even the smallest dose (one electron traversing a cell) may initiate carcinogenesis—for instance, from diagnostic x-ray sources (8,9). This claim is highly hypothetical and has resulted in medical, economic, and other societal harm.

The French Academies report (10) concluded that the LNT model and its use for assessing the risks associated with low doses are not based on scientific evidence. In contrast, the Biological Effects of Ionizing Radiation (BEIR) VII report (11) and that of the International Commission on Radiological Protection (ICRP) (12) recommended the use of the LNT model. We wish to update this debate by using recent radiation biologic and epidemiologic data.
Immediate Protections at Cell Level

Three types of immediately operating defense mechanisms have been identified:

Defenses against reactive oxygen species.—Oxygen metabolism, ionizing radiation, ultraviolet radiation, and other insults, such as an infection or physical exercise, can cause reactive oxygen species, with oxidative stress vitally counteracted by scavengers and antioxidant molecules (13,14). These defenses are less effective when the dose is high. Endogenous reactive oxygen species may cause up to about 8 DSBs per cell each day, similar to that induced by 200 mGy (or 0.14 mGy/min) (15,16), but these are less severe than radiation-induced DSBs.

DNA repair.—The repair mechanisms present in mammalian cells have existed in yeast for 800 million years. Deinococcus radiodurans bacteria have error-free repair mechanisms that can tolerate doses of 7 kGy (17); in multicellular organisms, the tolerance dose is much lower. Sensor molecules may detect DNA damage and activate signaling factors. In turn, these factors may induce cell cycle arrest and facilitate DNA repair and other defense mechanisms (18–24). The two main repair systems for DSBs are homologous recombination and nonhomologous end joining (NHEJ). The signaling network and the choice of the repair system are influenced by dose, dose rate, nature of radiation, and position of the cell in the cell cycle. At low doses of x-rays, homologous recombination is error free, while NHEJ is low error prone. The efficacy and fidelity of DNA repair diminishes with increasing amounts of DNA damage simultaneously present in a cell. Indeed, the carcinogenic risk is negligible (or nonexistent) at low doses and dose rates (6,21,25) and increases with higher doses and dose rates (21,24–26).

Checkpoints throughout the cell cycle allow for DNA repair or apoptosis and decrease the likelihood of aberrations and genomic instability in a dose-dependent manner (27,28). Also, contrary to former beliefs, the magnitude of the mutagenic effect (per unit dose) varies with dose rate (29,30), reaching a minimum in the range of 1–10 mGy/min, which corresponds approximately to the rate of reactive oxygen species–inducing DNA damage during oxidative stress (16). The probability of error during the repair of DSBs is low when DSBs are widely separated in space or time but increases drastically when multiple breaks are present simultaneously (26). In humans, intrachromosomal inversions and deletions are not induced by doses less than 100 mSv or at low dose rates (31–33). Also, large studies performed in vivo or in vitro have failed to reveal an increased incidence of chromosomal aberration at doses less than 20 mSv (34).

DNA repair also differs with type of damage, dose, and dose rate through signals from adjacent cells. Human fibroblasts repair DSBs more efficiently after a dose of 20 mGy than after a dose of 5 mGy, with no repair after a dose of 1.2 mGy in confluent cell cultures (1). Low-dose cellular hyperradiosensitivity (HRS) (35,36) decreases with increasing dose and disappears at doses higher than 0.5 Gy because of full repair activation. HRS eliminates at low doses potentially mutant cells, thereby reducing the carcinogenic risk. Defects in DNA repair systems are associated with a higher cancer incidence.
Elimination of damaged cells by death or proliferation arrest.—Elimination of cells with altered DNA, a crucial defense mechanism (38–42), may occur by apoptosis shortly after irradiation with doses ranging from a few to about 200 mSv. However, this mechanism of death is less important in most cell types at high doses when the number of cell deaths may cause tissue dysfunction.

At less than a few millisieverts, DNA repair is not activated, and mitotic cell death occurs on resumption of proliferation (1,41). For doses higher than 5 mSv, DNA repair is observed—for example, after computed tomographic (CT) scanning (doses of 10–20 mGy) (42).

Senescence is an alternative pathway for eliminating genetically defective cells without sacrifice of functional advantages before cell death (43–45).

Adaptive Responses
Besides immediate defenses against detrimental effects in irradiated cells, a stimulation of defenses is observed in neighboring hit and non-hit cells, including reactive oxygen species scavenging, DNA repair, and damaged cell removal by apoptosis and cell senescence. These may occur in mammalian cells with a delay of up to hours after low doses and may operate against renewed exposure to radiogenic and nonradiogenic genotoxins for hours to months, depending on the type of upregulation (46–49).

Such adaptive responses are observed in cultured cells and in rodents after doses of 1–500 mGy and disappear with higher doses. Moreover, spontaneously transformed cells may die because of cytokines released by nontransformed cells (50,51). Low-dose irradiation hours or days after a high dose also reduces some of the high-dose genotoxic effects (52). Adaptive responses exist in humans (53–55).

Bystander Effects
Irradiated cells may damage neighboring cells because of signals or products (bystander effects) that have been claimed to cause supralinear dose-effect relationships. However, recent results (56–58) suggest that on the contrary, irradiated cells also protect neighbors, thus acting as an adaptive response. Irradiated fish release products into the water that enhance the defenses against carcinogenesis of other fish swimming in the same water (59).

Furthermore, individuals contaminated with radium (60) or thorium (61) did not show excess cancer when the cumulative dose was less than a few gray. No carcinogenic bystander effect has been observed in these individuals (60,61). The proliferation and promotion of potentially mutant cells seems to be inhibited by normal cells surrounding irradiated cells, and only doses greater than a few gray with resulting massive cell damage promote carcinogenesis.

Genomic Instability
Persistent DNA damage causing chromosomal aberrations or aneuploidy may lead to genomic instability in cell progeny (62–65). However, doses less than 250 mSv of x or γ radiation yield no genetic instability (65–67). This also appears to pertain to low tissue doses from α particles in humans (10,16). The argument that low-dose irradiation can induce a genomic instability, which can in turn induce a cancer, is not based on convincing data. Moreover, some experimental data, such as those of Bouton et al (68), show that in mice there is no significant correlation between sensitivity to radiation-induced genomic instability and cancer induction.

Defenses at Tissue Level
Neighboring cells control the proliferation of each other (69–72). Several factors, such as infection and inflammation (71,73), facilitate the emergence of fully transformed clonal cells or enhance malignant clonal proliferation. Precancerous cells can acquire the capacity to overcome and also to manipulate protective mechanisms, in order to be recognized as a “friend” instead of being fought as a “foe” (72). Such situations occur after impairment of the microenvironment (74–76) or massive cell death following exposure to large amounts of any genotoxic agent (physical or chemical), with subsequent compensatory cell proliferation by homeostatic mechanisms (10,16). Tissue disorganization through disease also facilitates the escape of preneoplastic subclones from the barriers of the microenvironment. For example, liver cirrhosis and lung fibrosis increase the likelihood of cancer in the liver and lung.

Immune mechanisms counteract disease-promoting agents and kill abnormal cells (77–79). Immunosuppression often precedes cancer (80). Immune competence may be upregulated by low-dose radiation and reduce cancer risk (78,81).

When few cells are damaged, cell death seems the simplest way to avoid the presence of transformed cells (10,78). However, when the dose becomes higher than about 200 mGy, cellular impairment and death increase tissue endangerment; thus, DNA repair becomes mandatory despite the risk of misrepair and mutation. This conclusion is consistent with microarray data: (a) The sets of genes that are activated or repressed are not the same after a low or a high dose (82–84) or dose rate (85) and (b) the temporal gene expressions are also not the same after high doses (3 hours after a 2-Gy dose) and low doses (only after 48 hours for a 10-mGy dose) (84). This is consistent with proteomics and transcriptional changes being different at high and low doses, not only quantitatively but also qualitatively (86).

Hormesis
Upregulation of protective mechanisms at the cell and tissue levels by low doses likely also operates against carcinogenic factors other than ionizing radiation and against spontaneous cancer, as demonstrated in various experiments in vitro and in vivo (46,87–93). Indeed, a dose of 10 mGy reduces the rate of spontaneous transformation in culture cells below the background level. Some epide miologic data suggest that hormesis also exists in humans (94).

Summary
Biologic data demonstrate that the defense mechanisms against radiation-in-
duced carcinogenesis are powerful and diverse (Figure) (10,16,78,95,96). This is not surprising, because organisms have been subjected to reactive oxygen species from physiologic processes and environmental insults during evolution. Life is characterized by the ability to build defenses against toxic agents, whether internal or environmental. The defenses are overwhelmed at high doses and are stimulated at low doses, which is incompatible with the LNT model.

Epidemiologic Data

Analysis of the main studies reported on radiation-induced carcinogenesis leads us to conclude that there is no convincing evidence of a carcinogenic effect in humans or experimental animals for doses of less than 100 mGy of low linear energy transfer radiation (10,12,97). Little et al (98) have reached another conclusion, because their interpretations of some surveys differ.

Japanese Atomic Bomb Survivors

Leukemia.—Little and Muirhead (99,100) have shown that the dose response is not linear at doses less than 150 mSv. In fact, a quasi-threshold, or even a hormetic effect, may exist below this dose.

Solid tumors.—Preston et al (101,102) analyzed all solid tumors together. Because histologically distinct human tumors have widely different dose responses (103), mixing tumors leads to debatable results.

As epidemiologic data are inaccurate at low doses (104,105), one may fit them with a linear response relationship, a linear quadratic response relationship, a threshold somewhere between 40 and 60 mSv (101,102), or even a hormetic response relationship. Heidenreich et al (104) concluded that there was no significant increase in cancer incidence or mortality at doses less than 200 mSv, whereas other authors believe that this threshold is less than 100 mSv (9,11).

The concept that cancer induction proceeds similarly after low and high doses and dose rates is inconsistent with biologic evidence. Hence, assessments of low-dose risks in cohorts of atomic bomb survivors, radiation workers, or people exposed to radon at home included individuals who received more than 100 mSv and thus are subject to bias (105). When investigating risks at doses less than 100 mSv only, cancer excess is not seen. This does not exclude the possibility of an effect too small to be detectable, but suggests that the carcinogenic risk, if it exists, should be very low and of a debatable importance.

Atomic bomb survivors were also exposed to neutrons, of which small doses are potentially carcinogenic. A relative biological effectiveness (RBE) of 10 was used for calculating the dose equivalent (in sieverts). An RBE of 30 would have been more appropriate. Neutrons may explain the putative carcinogenic effect of low doses (104,106,107).

Confounding factors.—The atomic bomb survivors were exposed to radiation and to other carcinogenic agents. For example, the September 11, 2001, World Trade Center attack in New York City released into the environment a variety of toxins, causing first responders to suffer from acute aerodigestive symptoms with persistent respiratory inflammation and possibly granulomatous disease (108). Long-term effects are being investigated (109). The atomic bombs released far greater levels of nonradioactive toxins and caused burns, with chronic inflammation being potentially carcinogenic. Firefighters have increased cancer risks, suggesting that inhalation of carcinogenic and toxic compounds brings an occupational cancer risk (110–113).

In summary, the analyses of the atomic bomb data do not provide solid arguments for the LNT model.

In Utero Irradiation

There is the claim that prenatal irradiation with x-rays delivering a dose of 10–20 mGy increases cancer risk during childhood by about 40% (116). Results of a large case-control study did not support this finding (117). Among the confounding factors are the more frequent antenatal examinations with x-rays in older mothers and in mothers of high socioeconomic status, which are both factors known to be associated with an increased risk of childhood cancer (118). Underlying diseases leading to increased examinations with x-rays cannot be excluded as risks of childhood cancer (16). A Swedish population-based study matched children with leukemia with database records of instances of antenatal irradiation with x-rays (without recourse to interviews) and found no association between in utero irradiation and leukemias (119). Twins have a higher probability of in utero irradiation than singletons, and there was no increased leukemia risk (120,121). No increased cancer risk has been observed after in utero irradiation in atomic bomb survivors (122) or in experimental animals. Hence, the International Agency for Research on Cancer expert committee did not accept antenatal irradiation with x-rays as an established cancer risk factor (118).

Chernobyl Accident

Contrary to previous claims, there was no increase in leukemia or other cancers (except thyroid cancer) in regions contaminated after the Chernobyl accident where thyroid doses ranged up to 1 Sv (123). The increase in thyroid cancer among young children is correlated with dose (124), and a threshold at 200 mSv is compatible with data (125).

Occupational Exposure

An excess of skin cancer and leukemia was detected prior to 1950 in radiologists and radiologic technicians. Following the implementation of the recommendations of the ICRP in 1930, this excess decreased and disappeared among those beginning their practice after 1950, despite many receiving annual doses greater than 50 mSv (126–129). Similar data exist for airplane crews (130).

Among workers at nuclear power plants, a first study in 85 000 workers (131) did not reveal any increase in solid tumors but found a small increase in leukemia for those exposed to doses greater than 400 mSv. In a larger cohort (407 391 workers) studied subsequently (132), the cancer incidence after a cumulative dose of less than about 150 mSv was indistinguishable from that
in the control group. Questionably elevated cancer incidences were observed only in Canadian workers and in those at the Oak Ridge Laboratory (Oak Ridge, Tenn); these two cohorts included workers who were active during World War II, when dosimetry was not a main concern. Another study of Canadian workers who worked in later years (133) found a cancer mortality rate of 0.7 of that in the matched control population.

For large numbers of luminous dial workers contaminated with radium (60) and patients contaminated with thorium (61), follow-up was as long as that for atomic bomb survivors. Cancers (osteosarcoma or liver cancers) were not observed for doses less than a few gray (60,61,134).

High Background Radiation
Most studies around nuclear plants (135) have not detected any excess cases of cancers and leukemia or other diseases. Around some plants, a small excess of leukemia cases among children has been observed (136). However, this excess does not appear to be related to irradiation of children or their parents but rather to have been caused by a virus and population mixing (137–141).

People living in Kerala, India, experience lifetime terrestrial irradiation of up to 70 mSv a year, much higher than other populations in India, without an increased risk of carcinogenesis. In China (Yangjiang and its surrounding area), people are exposed to two levels of radiation per year—6.4 and 2.4 mSv, respectively. There was no increase in cancer or mortality (142,143), although the higher level of background radiation was confirmed by a higher incidence of chromosomal aberration (144). The existence of these aberrations despite the absence of a cancer excess is an argument in favor of the absence of a causal relationship between a chromosomal aberration and cancers.

Irradiation with X-rays for Diagnostic Examinations
Several studies in patients after x-ray–based examinations (145–147) have not detected any increase in leukemia or solid tumors. The only positive studies were in girls or young women after repeated chest fluoroscopic procedures for chronic tuberculosis (148,149) or scoliosis (150). Among these patients, excess breast cancer was detected only for cumulative doses greater than about 0.5 Gy. No other excess cancer appeared after cumulative doses up to 1 Gy. There was also no increased cancer after cardiac catheterization (147).

Several studies stressed the risk of cancer after diagnostic irradiation with x-rays by using the LNT model (8,9). However, several investigators (151–153) have questioned these estimates because of their doubtful assumptions. An overestimate of the diagnostic radiology risk may deprive patients from adequate treatment (154,155).

Radiation Therapy
One million patients each year undergo radiation therapy. By using cancer registries, investigators have indicated that the incidence of second primary cancers is incompatible with the LNT model and with the risk coefficients derived from Hiroshima and Nagasaki (103,156,157). The cumulative doses outside the target volume (158) ranged from a few milligrays to 60 Gy. A low dose rate (<15 mGy/min) reduced carcinogenesis not only in experimental animals (97,103) but also in patients (103,159,160). A dose per fraction of less than 120–160 mGy cumulating to about 3 Gy caused less carcinogenesis than higher doses per fraction (103,154,157). A threshold has been reported at about 0.6 Gy (corresponding to doses per fraction of 20 mGy); above this threshold, the dose-effect relationship appears to be quadratic (154).

An excess of solid tumors and leukemia has been observed in patients after treatment with several hundred millicuries of iodine 131 (154) for thyroid cancer (161). No excess cancer was detected among the large number of patients after they received 10–20 mCi (370–740 MBq) of $^{131}I$ for the treatment of hyperthyroidism (162). Moreover, a preliminary meta-analysis in 415 000 individuals exposed to less than 100 mSv showed no cancer excess (163).

$\alpha$ Particles are at least as carcinogenic as electrons. Therefore, the absence of cancer for doses less than a few grays, such as in patients who received Thorotrast and who have large numbers of cells that have been traversed by an $\alpha$ particle, cannot be overlooked (61,134).

Conclusion
There are potent defenses against the carcinogenic effects of ionizing radiation. Their efficacy is much higher for low doses and dose rates; this is incompatible with the LNT model but is consistent with current models of carcinogenesis (16). The data suggest that a combination of error-free DNA repair and elimination of preneoplastic cells furnishes practical thresholds (Figure).

For low linear energy transfer radiation, experimental animal data show the absence of carcinogenic effects for acute irradiation at doses less than 100 mSv and for chronic irradiation at doses less than 500 Sv (97,103,164).

Among humans, there is no evidence of a carcinogenic effect for acute irradiation at doses less than 100 mSv and for protracted irradiation at doses less than 500 mSv (10,103,147,163). Surveys of second primary malignancies in patients who have undergone radiation therapy should provide more information (103,154,157).

The fears associated with the concept of LNT and the idea that any dose, even the smallest, is carcinogenic lack scientific justification (10,16,78,163).

The Chernobyl accident showed that overestimating radiation risks could be more detrimental than underestimating them. Misinformation partially led to traumatic evacuations of about 200 000 individuals, an estimated 1250 suicides, and between 100 000 and 200 000 elective abortions outside the Union of Soviet Socialist Republics (164,165).

The DDREF attempts to overcome discrepancies between experimental or epidemiologic data and LNT predictions; it implies that for low doses and/or dose rates, the probability for DNA damage to be carcinogenic is reduced by half. However, the DDREF
leaves unchanged the highly debatable concept that even the smallest dose can induce cancer.

Overestimating the risks from diagnostic irradiation with x-rays may harm patients when appropriate studies are withheld for fear of potential malpractice (155).

The LNT model (with or without the DDREF) is inconsistent with biologic and experimental data, which show the nature and the effectiveness of immediate and delayed defense systems to vary widely with dose and dose rate. No convincing epidemiologic data support the LNT relationship. It has been said that for low doses, epidemiology faces its limits (166).

Defenses against the oxidative radicals created by water radiolysis are very effective for doses that create a number of radicals similar to those observed during oxidative stress. These defenses are poorer against high doses or dose rates greater than 0.5 Gy/min. DNA repair systems are very effective at low doses or dose rates (about 5–10 mGy/min) and become more error prone with increasing dose and dose rate.

The elimination of mutant cells by death or proliferation arrest is a crucial defense. Most human cancers display defects in apoptosis or other means of eliminating mutant cells (167). Damaged cells can be eliminated after low doses by means of death, senescence, or immune response.

Low-dose-rate irradiation (approximately 10 mGy/min) is less carcinogenic (per unit dose) than high-dose-rate irradiation (1 Gy/min). Fractionated irradiation is much less carcinogenic than acute irradiation owing to DNA repair during the time interval between fractions. Doses to normal tissue less than 150 mSv per radiation therapy fraction appear to be much less carcinogenic than higher doses (154,157).

All data suggest the existence of practical thresholds for carcinogenesis. This concept means that below the dose threshold, the carcinogenic risk, if it exists, is so small that it is without clinical importance. The fear of carcinogenesis from diagnostic x-ray examinations (eg, CT) that has been propagated is unjust. It is unethical to fuel anxiety with debatable hypotheses. A balance should be made between the risk, if any, of an x-ray examination and the medical information it provides (155). More human data are urgently needed and could be assembled by studying patients undergoing radiation therapy.

LNT was a useful model half a century ago. But current radiation protection concepts should be based on facts and on concepts consistent with current scientific results and not on opinions. Preconceived concepts impede progress; in the case of the LNT model, they have resulted in substantial medical, economic, and other societal harm.

References


29. Vilenchik MM, Knudson AG. Inverse radia-
tion dose-rate effects on somatic and germ-

30. Vilenchik MM, Knudson AG. Endogenous DNA double-strand break production, fi-


32. Zeng G, Day TK, Hooker AM, et al. Non-
linear chromosomal inversion response in prostate after low dose X-radiation expo-

33. Loucas BD, Eberle R, Bailey SM, Cornforth MN. Influence of dose rate on the induction of simple and complex chromosome ex-

34. UNSCEAR: United Nations Scientific Com-
mittee on the effects of atomic radiation. Sources, effects and risks of ionizing radia-


36. Krueger SA, Collis SJ, Joiner MC, Wilson GD, Marples B. Transition in survival from low dose hyper-radiosensitivity to in-
1271.

37. Löhrl M, Kühne M, Wetzel J, Rothkamm K. Joining of correct and incorrect double-

38. Bursch W, Lauer B, Timmermann-Trosse-
ner I, Barthel G, Schupper J, Schulte-
Hermann R. Controlled death (apoptosis) of normal and putative preneoplastic cells in rat liver following withdrawal of tumor promoters. Carcinogenesis 1984;5(4):453–
458.


40. Chandra J, Samali A, Orrenius S. Trigger-
ning and modulation of apoptosis by oxida-

anisms following low level radiation in-


44. Campisi J. Senescent cells, tumor suppres-

45. Schmitt CA. Cellular senescence and can-

46. Feinendegen LE, Pollycove M. Biologic re-
sponses to low doses of ionizing radiation: detrimen
t versus hormesis. I. Dose re-

47. Rigaud O, Moustacchi E. Radioadaptation 

48. Wolff S. The adaptive response in radiobi-

49. Broome EJ, Brown DL, Mitchell RE. Dose re-


51. Bauer G. Low dose radiation and intercellu-
lar induction of apoptosis: potential impli-

52. Day TK, Zeng G, Hooker AM, et al. Adap-


54. Stoilov LM, Mullenders LH, Darroudi F, Natarajan AT. Adaptive response to DNA and chromosomal damage induced by X-rays in human blood lymphocytes. Mu-

55. Ghassei-nejad M, Mortazavi SM, Cameron JR, Nioamond-rad A, Karan PA. Very high background radiation areas of Ram-

56. Mothersill C, Seymour CB. Radiation-in-
duced bystander effects and the DNA paradig-
mand: an “out of field” perspective. Mu-

57. Belvakov OV, Fokkard M, Mothersill C, Prise KM, Michael BD. Bystander induced differentiation: a major response to tar-

58. Schettino G, Fokkard M, Michael BD, Prise 
KM. Low-dose binary behavior of by-

stnder cell killing after microbeam irradia-

59. Smith RW, Wang J, Bucking CP, Mothersill 
CE, Seymour CB. Evidence for a protective response by the gliel proteome of rainbow trout exposed to X-ray induced bystander signals. Proteomics 2007;7(22):4171–
4180.

60. Carnes BA, Groer PG, Koteck TJ. Radiation dial workers: issues concerning dose re-


141. Rudant J, Baccaini B, Ripert M, et al. Population-mixing at the place of residence at...


Radiology 2009
This is your reprint order form or pro forma invoice
(Please keep a copy of this document for your records.)

Reprint order forms and purchase orders or prepayments must be received 72 hours after receipt of form either
by mail or by fax at 410-820-9765. It is the policy of Cadmus Reprints to issue one invoice per order.
Please print clearly.

<table>
<thead>
<tr>
<th>Author Name</th>
<th>Title of Article</th>
<th>Issue of Journal</th>
<th>Reprint #</th>
<th>Publication Date</th>
<th>Number of Pages</th>
<th>KB #</th>
<th>Symbol</th>
<th>Color in Article?</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Color in Article?</th>
<th>Yes / No (Please Circle)</th>
</tr>
</thead>
</table>

Please include the journal name and reprint number or manuscript number on your purchase order or other correspondence.

Order and Shipping Information

<table>
<thead>
<tr>
<th>Reprint Costs (Please see page 2 of 2 for reprint costs/fees.)</th>
<th>Shipping Address (cannot ship to a P.O. Box) Please Print Clearly</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Number of reprints ordered</th>
<th>$</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of color reprints ordered</td>
<td>$</td>
</tr>
<tr>
<td>Number of covers ordered</td>
<td>$</td>
</tr>
</tbody>
</table>

Subtotal $_______

Taxes $_______

(Add appropriate sales tax for Virginia, Maryland, Pennsylvania, and the District of Columbia or Canadian GST to the reprints if your order is to be shipped to these locations.)

First address included, add $32 for each additional shipping address $_______

TOTAL $_______

Payment and Credit Card Details

Enclosed: Personal Check ______ Credit Card Payment Details ______

Checks must be paid in U.S. dollars and drawn on a U.S. Bank.

Credit Card:   _ VISA   _ Am. Exp.   _ MasterCard

Card Number ___________________________ Expiration Date __________

Signature: ____________________________________________

Please send your order form and prepayment made payable to:

Cadmus Reprints
P.O. Box 751903
Charlotte, NC 28275-1903

Note: Do not send express packages to this location, PO Box.

FEIN #: 541274108

Signature ___________________________ Date __________________

Signature is required. By signing this form, the author agrees to accept the responsibility for the payment of reprints and/or all charges described in this document.

Invoice or Credit Card Information

<table>
<thead>
<tr>
<th>Invoice Address</th>
<th>Please Print Clearly</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Name</th>
<th>Institution</th>
<th>Street</th>
<th>City</th>
<th>State</th>
<th>Zip</th>
</tr>
</thead>
</table>

Country   ___________________________________________

Quantity ____________________ Fax ___________________

Phone: Day __________________ Evening ______________

E-mail Address ______________________________________

Additional Shipping Address* (cannot ship to a P.O. Box)

<table>
<thead>
<tr>
<th>Name</th>
<th>Institution</th>
<th>Street</th>
<th>City</th>
<th>State</th>
<th>Zip</th>
</tr>
</thead>
</table>

Country   ___________________________________________

Quantity ____________________ Fax ___________________

Phone: Day __________________ Evening ______________

E-mail Address ______________________________________

* Add $32 for each additional shipping address

Cadmus will process credit cards and Cadmus Journal Services will appear on the credit card statement.

If you don’t mail your order form, you may fax it to 410-820-9765 with your credit card information.

Signature __________________________________________

Date ______________________________________________

Page 1 of 2
**Black and White Reprint Prices**

<table>
<thead>
<tr>
<th># of Pages</th>
<th>50</th>
<th>100</th>
<th>200</th>
<th>300</th>
<th>400</th>
<th>500</th>
</tr>
</thead>
<tbody>
<tr>
<td>1-4</td>
<td>$239</td>
<td>$260</td>
<td>$285</td>
<td>$303</td>
<td>$323</td>
<td>$340</td>
</tr>
<tr>
<td>5-8</td>
<td>$379</td>
<td>$420</td>
<td>$455</td>
<td>$491</td>
<td>$534</td>
<td>$572</td>
</tr>
<tr>
<td>9-12</td>
<td>$507</td>
<td>$560</td>
<td>$651</td>
<td>$684</td>
<td>$748</td>
<td>$814</td>
</tr>
<tr>
<td>13-16</td>
<td>$627</td>
<td>$698</td>
<td>$784</td>
<td>$868</td>
<td>$954</td>
<td>$1,038</td>
</tr>
<tr>
<td>17-20</td>
<td>$755</td>
<td>$845</td>
<td>$947</td>
<td>$1,064</td>
<td>$1,166</td>
<td>$1,272</td>
</tr>
<tr>
<td>21-24</td>
<td>$878</td>
<td>$985</td>
<td>$1,115</td>
<td>$1,250</td>
<td>$1,377</td>
<td>$1,518</td>
</tr>
<tr>
<td>25-28</td>
<td>$1,003</td>
<td>$1,136</td>
<td>$1,294</td>
<td>$1,446</td>
<td>$1,607</td>
<td>$1,757</td>
</tr>
<tr>
<td>29-32</td>
<td>$1,128</td>
<td>$1,281</td>
<td>$1,459</td>
<td>$1,632</td>
<td>$1,819</td>
<td>$2,002</td>
</tr>
<tr>
<td>Covers</td>
<td>$149</td>
<td>$164</td>
<td>$219</td>
<td>$275</td>
<td>$335</td>
<td>$393</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th># of Pages</th>
<th>50</th>
<th>100</th>
<th>200</th>
<th>300</th>
<th>400</th>
<th>500</th>
</tr>
</thead>
<tbody>
<tr>
<td>1-4</td>
<td>$247</td>
<td>$267</td>
<td>$385</td>
<td>$515</td>
<td>$650</td>
<td>$780</td>
</tr>
<tr>
<td>5-8</td>
<td>$297</td>
<td>$345</td>
<td>$655</td>
<td>$923</td>
<td>$1,194</td>
<td>$1,467</td>
</tr>
<tr>
<td>9-12</td>
<td>$445</td>
<td>$563</td>
<td>$926</td>
<td>$1,339</td>
<td>$1,748</td>
<td>$2,162</td>
</tr>
<tr>
<td>13-16</td>
<td>$587</td>
<td>$710</td>
<td>$1,201</td>
<td>$1,748</td>
<td>$2,297</td>
<td>$2,843</td>
</tr>
<tr>
<td>17-20</td>
<td>$738</td>
<td>$858</td>
<td>$1,474</td>
<td>$2,167</td>
<td>$2,846</td>
<td>$3,532</td>
</tr>
<tr>
<td>21-24</td>
<td>$888</td>
<td>$1,005</td>
<td>$1,750</td>
<td>$2,575</td>
<td>$3,400</td>
<td>$4,230</td>
</tr>
<tr>
<td>25-28</td>
<td>$1,035</td>
<td>$1,164</td>
<td>$2,034</td>
<td>$2,986</td>
<td>$3,957</td>
<td>$4,912</td>
</tr>
<tr>
<td>29-32</td>
<td>$1,186</td>
<td>$1,311</td>
<td>$2,302</td>
<td>$3,402</td>
<td>$4,509</td>
<td>$5,612</td>
</tr>
<tr>
<td>Covers</td>
<td>$149</td>
<td>$164</td>
<td>$219</td>
<td>$275</td>
<td>$335</td>
<td>$393</td>
</tr>
</tbody>
</table>

Minimum order is 50 copies. For orders larger than 500 copies, please consult Cadmus Reprints at 800-407-9190.

**Reprint Cover**

Cover prices are listed above. The cover will include the publication title, article title, and author name in black.

**Shipping**

Shipping costs are included in the reprint prices. Domestic orders are shipped via FedEx Ground service. Foreign orders are shipped via a proof of delivery air service.

**Multiple Shipments**

Orders can be shipped to more than one location. Please be aware that it will cost $32 for each additional location.

**Delivery**

Your order will be shipped within 2 weeks of the journal print date. Allow extra time for delivery.

---

**Color Reprint Prices**

<table>
<thead>
<tr>
<th># of Pages</th>
<th>50</th>
<th>100</th>
<th>200</th>
<th>300</th>
<th>400</th>
<th>500</th>
</tr>
</thead>
<tbody>
<tr>
<td>1-4</td>
<td>$247</td>
<td>$267</td>
<td>$385</td>
<td>$515</td>
<td>$650</td>
<td>$780</td>
</tr>
<tr>
<td>5-8</td>
<td>$297</td>
<td>$345</td>
<td>$655</td>
<td>$923</td>
<td>$1,194</td>
<td>$1,467</td>
</tr>
<tr>
<td>9-12</td>
<td>$445</td>
<td>$563</td>
<td>$926</td>
<td>$1,339</td>
<td>$1,748</td>
<td>$2,162</td>
</tr>
<tr>
<td>13-16</td>
<td>$587</td>
<td>$710</td>
<td>$1,201</td>
<td>$1,748</td>
<td>$2,297</td>
<td>$2,843</td>
</tr>
<tr>
<td>17-20</td>
<td>$738</td>
<td>$858</td>
<td>$1,474</td>
<td>$2,167</td>
<td>$2,846</td>
<td>$3,532</td>
</tr>
<tr>
<td>21-24</td>
<td>$888</td>
<td>$1,005</td>
<td>$1,750</td>
<td>$2,575</td>
<td>$3,400</td>
<td>$4,230</td>
</tr>
<tr>
<td>25-28</td>
<td>$1,035</td>
<td>$1,164</td>
<td>$2,034</td>
<td>$2,986</td>
<td>$3,957</td>
<td>$4,912</td>
</tr>
<tr>
<td>29-32</td>
<td>$1,186</td>
<td>$1,311</td>
<td>$2,302</td>
<td>$3,402</td>
<td>$4,509</td>
<td>$5,612</td>
</tr>
<tr>
<td>Covers</td>
<td>$149</td>
<td>$164</td>
<td>$219</td>
<td>$275</td>
<td>$335</td>
<td>$393</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th># of Pages</th>
<th>50</th>
<th>100</th>
<th>200</th>
<th>300</th>
<th>400</th>
<th>500</th>
</tr>
</thead>
<tbody>
<tr>
<td>1-4</td>
<td>$306</td>
<td>$321</td>
<td>$467</td>
<td>$642</td>
<td>$811</td>
<td>$986</td>
</tr>
<tr>
<td>5-8</td>
<td>$387</td>
<td>$517</td>
<td>$816</td>
<td>$1,154</td>
<td>$1,498</td>
<td>$1,844</td>
</tr>
<tr>
<td>9-12</td>
<td>$574</td>
<td>$689</td>
<td>$1,157</td>
<td>$1,686</td>
<td>$2,190</td>
<td>$2,717</td>
</tr>
<tr>
<td>13-16</td>
<td>$754</td>
<td>$874</td>
<td>$1,506</td>
<td>$2,193</td>
<td>$2,883</td>
<td>$3,570</td>
</tr>
<tr>
<td>17-20</td>
<td>$710</td>
<td>$1,063</td>
<td>$1,852</td>
<td>$2,722</td>
<td>$3,572</td>
<td>$4,428</td>
</tr>
<tr>
<td>21-24</td>
<td>$1,124</td>
<td>$1,242</td>
<td>$2,195</td>
<td>$3,231</td>
<td>$4,267</td>
<td>$5,300</td>
</tr>
<tr>
<td>25-28</td>
<td>$1,320</td>
<td>$1,440</td>
<td>$2,541</td>
<td>$3,738</td>
<td>$4,957</td>
<td>$6,153</td>
</tr>
<tr>
<td>29-32</td>
<td>$1,498</td>
<td>$1,616</td>
<td>$2,888</td>
<td>$4,269</td>
<td>$5,649</td>
<td>$7,028</td>
</tr>
<tr>
<td>Covers</td>
<td>$211</td>
<td>$224</td>
<td>$324</td>
<td>$444</td>
<td>$558</td>
<td>$672</td>
</tr>
</tbody>
</table>

**Tax Due**

Residents of Virginia, Maryland, Pennsylvania, and the District of Columbia are required to add the appropriate sales tax to each reprint order. For orders shipped to Canada, please add 7% Canadian GST unless exemption is claimed.

**Ordering**

Reprint order forms and purchase order or prepayment is required to process your order. Please reference journal name and reprint number or manuscript number on any correspondence. You may use the reverse side of this form as a proforma invoice. Please return your order form and prepayment to:

**Cadmus Reprints**
P.O. Box 751903
Charlotte, NC  28275-1903

Note: Do not send express packages to this location, PO Box.
FEIN #:541274108

Please direct all inquiries to:

**Rose A. Baynard**
800-407-9190 (toll free number)
410-819-3966 (direct number)
410-820-9765 (FAX number)
baynardr@cadmus.com (e-mail)

---

Reprint Order Forms and purchase order or prepayments must be received 72 hours after receipt of form.